LNLinh Chang Nguyen

Linh Chang Nguyen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Linh Chang Nguyen has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Johannes Metternich

    Technische Universität Berlin, Faculty IV Electrical Engineering and Computer Science, Marchstraße 23, 10587 Berlin, Germany, Germany

    1 shared publication
  • Mariia Babaeva

    Charité – Universitätsmedizin Berlin, Charité Medical Faculty, Charité Campus Mitte, Charitéplatz 1, 10117 Berlin, Germany, Germany

    1 shared publication
  • Mariia Myshkina

    Humboldt-Universität zu Berlin, Faculty of Life Sciences, Department of Biology, Institute of Theoretical Biology, Systems Medicine of the Liver, Unter den Linden 6, 10099 Berlin, Germany, Germany

    1 shared publication
  • Matthias König

    Faculty of Life Science, Institute for Biology , Humboldt-Universität zu Berlin , Berlin , Germany

    1 shared publication
  • Michelle Elias

    Humboldt-Universität zu Berlin, Faculty of Life Sciences, Department of Biology, Institute of Theoretical Biology, Systems Medicine of the Liver, Unter den Linden 6, 10099 Berlin, Germany, Germany

    1 shared publication
  • Shelee Bedón

    Freie Universität Berlin, Institute of Pharmacy, Königin‑Luise‑Straße 2+4, 14195 Berlin, Germany, Germany

    1 shared publication

Latest Publications

  • Open Access

    An Open and Reproducible Digital Twin for Personalised Anticoagulant Therapy: Modelling Apixaban Pharmacokinetics and Pharmacodynamics

    by Mariia Myshkina, Mariia Babaeva, Linh Chang Nguyen, Shelee Bedón, Johannes Metternich, Michelle Elias, Matthias König

    Background: Thrombotic events increase with age, necessitating anticoagulants with reliable pharmacokinetic (PK) and pharmacodynamic (PD) profiles. Apixaban has important therapeutic advantages, but individualised dosing remains challenging because exposure and response are influenced by renal and hepatic function, food intake, body weight, and other patient-specific factors. Existing physiologically based pharmacokinetics/pharmacodynamics (PBPK/PD) models are limited by data sources, transparency, and incomplete representation of metabolites and pharmacodynamics. Methods: A systematic literature review identified 35 apixaban PK/PD clinical studies, which were curated and used for model development, parameter optimisation, and evaluation. We developed an expanded whole-body PBPK/PD model of apixaban with explicit metabolite representation and enhanced pharmacodynamic components. The model follows a modular structure and is encoded in SBML to support interoperability and reproducibility. Results: The model reproduced observed clinical PK/PD data across all 35 studies, covering diverse doses, regimens, and populations. Simulations captured apixaban PK and PD under normal conditions and clinically relevant scenarios, including renal and hepatic impairment, fasted and fed states, and obesity. Conclusions: This open PBPK/PD digital twin provides quantitative insight into determinants of apixaban exposure and response. All model files, documentation, simulation scripts, and curated datasets are openly available under MIT and CC-BY licenses following FAIR principles.